Jacobs Levy Equity Management
SONM icon

Jacobs Levy Equity Management’s DNA X Inc SONM Stock Holding History

Jacobs Levy Equity Management’s Portfolio SONM Stock Details SONM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-42
Closed -$53K – 1146
2020
Q1 		$53K Sell
42
-2
-5% -$9.58K ﹤0.01% 980
2019
Q4 		$286K Buy
+44
New +$217K ﹤0.01% 863

Other funds holding SONM

BRF
B. Riley Financial Los Angeles, California $456M AUM 896.07% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
NC
Nokomis Capital Dallas, Texas $349M AUM 75.66% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
HIM
Herald Investment Management London, United Kingdom $737M AUM 158.15% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return

Jacobs Levy Equity Management's SONM Position: Q2 2020 in Review

Jacobs Levy Equity Management sold out of DNA X Inc (SONM) in Q2 2020, closing a stake of 42 shares — an estimated $53K sold.

Jacobs Levy Equity Management first reported a position in SONM in Q4 2019 and held it in 2 quarters. The position peaked at $286K in Q4 2019. 39 funds tracked by Wall St. Rank hold SONM as of Q2 2020.

  • Jacobs Levy Equity Management reported no remaining DNA X Inc position as of Q2 2020 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 42 DNA X Inc shares in Q2 2020, an estimated $53K.
  • Jacobs Levy Equity Management first reported a position in DNA X Inc in Q4 2019 and held it in 2 quarters.
  • Jacobs Levy Equity Management's DNA X Inc position peaked at $286K in Q4 2019.
  • 39 funds tracked by Wall St. Rank held DNA X Inc as of Q2 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2020, filed 17 Aug 2020.